The Week in Review: Support for China Pharma in Five-Year Plan

China earmarked 2 trillion RMB ($309 billion) for science and technology in its 2011-2015 Five-Year Plan; Jointown Pharma and 360buy.com will form an online pharma JV to sell directly to consumers; Wuhan Kindstar Diagnostics raised $11 million to support its China laboratory testing service; MediciNova of San Diego formed a China asthma JV with Zhejiang Medicine; Harbin Gloria Pharma’s impending deal to acquire Heilongjiang Dilong Pharma has fallen apart; Microbix Biosystems of Canada put its China flu JV on hold; Boston Therapeutics out-licensed the China rights for an OTC glucose control treatment to Advance Pharma of Hong Kong; Walvax Biotech received board approval for a $112 million building project; and Sinovac Biotech of Beijing will begin a Phase II clinical trial of its EV71 vaccine. More details…. Stock Symbols: (NSDQ: MNOV) (JSDQ: 4875) (SHA: 600216) (SHE: 002437) (TSX: MBX) (SHE: 300142) (NSDQ: SVA) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});